Je was op zoek naar: dmard (Engels - Estisch)

+ dmard
+ hmr

pbo + dmard
pbo + hmr

pbo + mtx/ dmard
pbo + mtx/ dmard

8 mg/ kg dmard + dmard
tcz pbo + 8 mg/ kg dmard + dmard

dmard - disease modifying anti-rheumatic drug
hmr - haigust modifitseeriv antireumaatiline ravim

pbo + mtx/ dmard ** - p < 0.01, tcz vs.
pbo + mtx/ dmard ** - p < 0, 01, tcz vs.

all patients received background non-biologic dmard(s).
kõik patsiendid said foonravi mittebioloogilis(t)e dmardi(de)ga.

these results were maintained over 52 weeks of treatment in dmard-naïve subjects.
need tulemused säilisid 52 nädala jooksul dmard-ravi mittesaanud patsientide ravis.

evaluation for treatment of signs and symptoms and inhibition of structural damage in dmard naïve patients.
nähtude ja sümptomite ravi ning strukturaalsete kahjustuste inhibeerimise hindamine dmard-ravi varem mittesaanud patsientidel.

in patients with rheumatoid arthritis, 283 patients received subsequent therapy with a biologic dmard following mabthera.
283 reumatoidartriidiga patsienti said mabthera-ravi järgselt ravi bioloogilise dmardiga.

study vii with 12-week duration, treated 100 patients who had an inadequate response to dmard therapy.
uuring vii kestis 12 nädalat ning hõlmas 100 patsienti, kelle vastus ravile haigust moduleerivate antireumaatiliste ravimitega jäi ebapiisavaks.

psa study ii with 12 -week duration, treated 100 patients who had an inadequate response to dmard therapy.
psa uuring ii kestis 12 nädalat ning hõlmas 100 patsienti, kelle vastus ravile haigust moduleerivate antireumaatiliste ravimitega jäi ebapiisavaks.

patients had a mean time since diagnosis at baseline of 2.9 months and were dmard naïve (including mtx).
keskmine periood diagnoosist oli 2,9 kuud ning patsiendid ei olnud dmard-ravi saanud (sh mtx).

≥ 3 tender joints) despite non-steroidal anti-inflammatory (nsaid) or dmard therapy.
põletiku vähenemine sakroiliakaalses liigeses (si) mrt põhjal

the long-term safety of enbrel in combination with other disease-modifying antirheumatic drugs (dmard) has not been established.
enbreli pikaajalist ohutust kombinatsioonis teiste haiguse kulgu modifitseerivate reumavastaste ravimitega (hmr) ei ole kindlaks tehtud.

concomitant administration of hepatotoxic or haematotoxic dmards (e.g. methotrexate) is not advisable.
samaaegne ravi hepatotoksilise või hematotoksilise hmr-iga (nt metotreksaat) pole soovitatav.